Nitric oxide (NO) is an essential signaling molecule in biological systems. In mammals, the diatomic gas is critical to the cyclic guanosine monophosphate (cGMP) pathway as it functions as the primary activator of soluble guanylate cyclase (sGC). NO is synthesized from L-arginine and oxygen (O 2 ) by the enzyme nitric oxide synthase (NOS). Once produced, NO rapidly diffuses across cell membranes and binds to the heme cofactor of sGC. sGC forms a stable complex with NO and carbon monoxide (CO), but not with O 2 . The binding of NO to sGC leads to significant increases in cGMP levels. The second messenger then directly modulates phosphodiesterases (PDEs), ion-gated channels, or cGMP-dependent protein kinases to regulate physiological functions, including vasodilation, platelet aggregation, and neurotransmission. Many studies are focused on elucidating the molecular mechanism of sGC activation and deactivation with a goal of therapeutic intervention in diseases involving the NO/cGMP-signaling pathway. This review summarizes the current understanding of sGC structure and regulation as well as recent developments in NO signaling. 
INTRODUCTION
The nitric oxide/cyclic guanosine monophosphate (NO/cGMP) pathway was discovered in the 1980s, but chemical modulation of the pathway for the treatment of angina pectoris had been unknowingly achieved 100 years earlier. This stimulation of cGMP production occurred with the clinical administration of organic nitrites (isoamyl nitrite) (1) and organic nitrates (glyceryl trinitrate; GTN) (2) . These compounds alleviate the pain associated with angina by relaxing the vascular smooth muscle, leading to vasodilation. For years, investigations were focused on the mechanism of smooth muscle relaxation by these molecules, and these efforts led to the discovery that NO is a physiologically relevant signaling molecule. Additionally, these efforts led to the identification of the enzymes that biosynthesize NO and cGMP.
Enzymes Critical to the Nitric Oxide/Cyclic Guanosine Monophosphate Pathway
Early studies showed that both cytosolic and particulate fractions of mammalian tissue exhibit guanylate cyclase activity. Within the insoluble fractions, membrane-bound particulate guanylate cyclases are present, which are activated by natriuretic peptides (reviewed in References 3 and 4), whereas the cytosolic fractions contain soluble guanylate cyclases (sGCs), which are activated by NO. NO-responsive guanylate cyclase activity is also associated with cell membranes in certain tissues, including skeletal muscle and brain, as well as in platelets (5) (6) (7) . Guanylate cyclases are found in most tissues, and the distribution of these proteins in various cells is isoform specific. This provides an additional means to regulate cGMP-dependent responses because localized pools of the signaling molecule can be generated within specific tissues and in proximity to either soluble or membranebound cGMP receptors. Thus, tissues can cGMP: cyclic guanosine monophosphate
GTN: glyceryl trinitrate
Vasodilation: blood vessel widening from smooth muscle relaxation sGC: soluble guanylate cyclase NOS: nitric oxide synthase regulate cGMP levels by expression of specific GC isoforms, and the isoforms have a distinct peptide receptor or ligand activator. Additionally, a reciprocal communication between particulate guanylate cyclase and sGC has been observed in the regulation of human and mouse vascular homeostasis (8) , and it remains likely that communication between these pathways occurs in several cGMP-dependent processes.
Generally, in eukaryotic NO signaling, the initial event involves calcium release, followed by binding of a calcium/calmodulin complex to nitric oxide synthase (NOS), which activates the enzyme. NO is synthesized and then diffuses into target cells, where it binds to the heme in sGC (Figure 1 ). sGC is a histidine-ligated hemoprotein that binds NO and carbon monoxide (CO), but not oxygen (O 2 ). This binding event leads to a several hundredfold increase in cGMP synthesis. Once formed, cGMP targets include phosphodiesterases (PDEs), ion-gated channels, and cGMP-dependent protein kinases in the regulation of several physiological functions, including vasodilation, platelet aggregation, and neurotransmission (9) (10) (11) .
In 1998, the Nobel Prize in Physiology or Medicine was awarded to Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad, in recognition of their achievements toward the discovery of the NO-signaling pathway. Currently, this pathway is actively studied because drugs modulating NO-dependent processes have the potential to treat several maladies, including cardiovascular and neurodegenerative diseases, as well as various airway diseases.
ISOLATION OF SOLUBLE GUANYLATE CYCLASE
Despite many years of research on sGC, an efficient low-cost purification of the protein has The nitric oxide/cyclic GMP (NO/cGMP)-signaling pathway. A Ca 2+ /calmodulin (CaM) complex binds nitric oxide synthase (NOS). NOS catalyzes the oxidation of L-arginine (L-Arg) to L-citrulline (L-Cit) and nitric oxide (NO) . NO binds to the Fe II heme of α1β1 soluble guanylate cyclase (sGC) at a diffusioncontrolled rate. This binding event leads to significant increases in cGMP and pyrophosphate (PP i ). cGMP then binds to and activates cGMP-dependent protein kinases (cGKs), phosphodiesterases (PDEs) and ion-gated channels. Abbreviations: α1 and β1, soluble guanylate cyclase subunits; CaM, calmodulin.
GTP: guanosine 5 -triphosphate remained elusive, but several methods have been developed that yield low microgram amounts of homogeneous protein. Initial characterization of sGC was carried out with protein obtained from rat and bovine tissues. By the 1980s, studies were being done with purified sGC from rat lung (12) and liver (13) , as well as from bovine lung (14, 15) ; these studies showed sGC to be a heterodimer. Importantly, it was observed that sGC could be purified with and without the heme cofactor, depending on the purification protocol. In short, the use of solubilizing agents or ammonium sulfate precipitation can lead to misfolded apoprotein. Heme reconstitution of this apoprotein yields an sGC species [later termed sGC 1 by Vogel et al. (16) ] with biochemical properties that vary from the native protein [named sGC 2 by Vogel et al. (16) ]. To date, the bovine lung sGC prep is the most efficient method of isolating heme-bound protein from source tissue (17, 18) . This method typically yields ∼1 mg of pure protein per kilogram of lung.
The development of heterologous expression systems for recombinant sGC expression led to significant advances. The first successful heterologous expression system for sGC was accomplished in COS-7 cells (19) . Although COS-7 cells do not produce enough sGC for protein purification, the procedure was pivotal to establishing that sGC is an obligate heterodimer composed of α1 and β1 subunits (20) . Additionally, COS-7 cells have been used to examine mutants and truncations of sGC via lysate activity assays (21, 22) .
The overexpression of rat sGC in insect cells with the Sf9/baculovirus expression system was the first procedure used to isolate pure recombinant protein (21, 23, 24) . sGC expression in insect cells was initially accomplished without an affinity tag (21), but current protocols involve a His tag to facilitate the purification process (25) (26) (27) . Although highly expressed, most (>90%) of the protein is insoluble. This method typically yields 0.2-0.4 mg of pure soluble protein per liter of culture and is now commonly used to obtain purified rat and human sGC. A clear advantage of the Sf9/baculovirus expression system is that it enables in vitro characterization, including the generation of site-directed mutants. However, both the COS-7 and Sf9/baculovirus expression systems facilitated the biochemical characterization of subunit dimerization, allowed for the generation of site-directed mutants, and provided larger quantities of enzyme for in vitro studies.
The full-length mammalian α1β1 heterodimer has not yet been isolated from a bacterial expression system, but several truncations of sGC have been successfully obtained via expression in Escherichia coli. These proteins include N-terminal truncations of α1, β1, and β2 (28-30), C-terminal truncations of α1 and β1 (31, 32) , and a domain within the central region of β1 (Figure 2 ) (31) . These constructs purify with yields ranging from 0. of pure protein per liter of culture. Recently an E. coli expression system was used for the full-length Manduca sexta α1β1 heterodimer (33) . This method provides low amounts (0.5-1 mg/liter) of partially pure full-length protein, but higher yields (1-2 mg/liter) of pure protein were obtained by truncating the C terminus of the α1 and β1 subunits (33) . The resulting heterodimeric proteins (msGC-NT1 and msGC-NT2) lack the ability to cyclize GTP but can be purified to homogeneity. Perhaps future work optimizing the expression conditions and/or purification of sGC from E. coli will overcome the current limitations in protein yield.
SOLUBLE GUANYLATE CYCLASE ISOFORMS
Heterodimeric sGC consists of two homologous subunits, α and β. The most commonly studied isoform is the α1β1 protein; however, α2 and β2 subunits have also been identified (34, 35) . These proteins were first characterized in mammals, but they also exist in insects, such as Drosophila melanogaster and M. sexta, and in fish. Isoforms of α-subunits are highly homologous with ∼48% sequence identity, and β-subunits have an overall sequence identity of ∼41%.
The localization of each subunit has been studied in mammals, including humans, rats, and cows. Both α1 and β1 subunits are expressed in most tissues, and it is well accepted that these proteins form a physiologically relevant heterodimer (36) . By quantitative polymerase chain reaction analysis and Western blotting, the α2 subunit is found in fewer tissues when compared to the α1 and β1 isoforms but is highly expressed in the brain, lung, colon, heart, spleen, uterus, and placenta (36) . Studies with purified protein have shown that the α2β1 heterodimer exhibits ligand-binding characteristics identical to the α1β1 heterodimer (37, 38) , but a splice variant of the α2 subunit (α2i) forms a dimer with the β1 subunit to form an inactive complex. α2i contains an in-frame insertion of 31 amino acids within the catalytic domain and appears to function as a dominant-negative protein (39) . Despite the similar biochemical properties of the two physiologically relevant sGC heterodimers, they have unique roles in cGMP signaling that may be attributed to their varying cellular localization. Specifically, α2β1 has been associated with the membrane in several tissues (5-7), and consequently, α2β1 responds differently than cytosolic α1β1 (37). In rat brain, it was found that this association is mediated by an interaction between the C terminus of the α2 protein and PSD-95 (postsynaptic density-95) protein (6) . Most recently, a distinct presynaptic role has been identified for α1β1 in glutamate release in the hippocampus (40) .
The β2 isoform is not ubiquitously expressed like the β1 isoform, and analysis of mRNA levels indicates that it is found primarily in the kidney (35) . Unlike β1, the C terminus of β2 contains a possible isoprenylation site, but the subcellular localization of this protein is unknown. The β2 isoform has not yet been purified and characterized, but the protein has been studied after transient expression in insect cells. Using this approach, it was found that β2 does not exhibit cyclase activity when expressed with α1 or α2 but that β2 is active in the absence of an α-subunit, suggesting that the β2 protein can function as a homodimer ex vivo (41) . This is in contrast to the β1 protein, which has been isolated as an inactive homodimer after overexpression in insect cells (26) . In rat kidney, the mRNA levels of the β2 subunit were shown to be developmentally regulated (42) ; however, it remains unclear what the physiological role of the β2 isoform is in cGMP signaling.
Recently, several genetic studies in mouse models have emphasized the importance of the various sGC isoforms for physiological processes (reviewed in Reference 43). Knockout mice lacking the sGC β1 subunit exhibit elevated blood pressure, reduced heart rate, and dysfunction in gastrointestinal contractility (44) . Additionally, deletion of the β1 subunit within only smooth muscle cells implicates the loss of the protein in these cells as the cause of hypertension in the knockout mice (45) . Deletion of the β1 subunit is generally viewed PAS: protein fold named for its association with the Per, ARNT, and Sim proteins H-NOX: heme-nitric oxide and oxygen binding as a global sGC knockout because α1 and α2 do not form functional heterodimers with β2. sGC α1 and α2 knockout mice have also been generated. Both proteins were found to be essential for long-term potentiation (46) , and vasodilation was mediated primarily by the α1 isoform (47) . In addition to clarifying the role of the α1β1 protein in NO-mediated pulmonary vasodilation (48, 49) , studies with α1 subunitdeficient mice suggest that both α-subunits are involved in gastric nitrergic relaxation (50) and relaxation of colon tissue (51) .
Several invertebrates also contain genes that encode predicted NO-sensitive guanylate cyclases. Likely owing to the genetic tools available in D. melanogaster, this organism contains the best-characterized insect guanylate cyclase. In D. melanogaster, Gycα-99B and Gycβ-100B are orthologs of the α1 and β1 subunits, respectively. Drosophila mutants deficient in the production of these proteins suggest that the NO/cGMP pathway mediates a behavioral phenotype (52) and development of the visual system (53) , and this pathway is important for larval foraging locomotion (54) . In other organisms, several biochemical studies have been aimed at elucidating the significance of the NO/cGMP-signaling pathway. As mentioned above, the full-length M. sexta α1β1 heterodimer has recently been characterized (33) . There is evidence that sGC in M. sexta is involved in neuronal excitability (55) and odor responsiveness (56) . In mollusks, such as the Limax marginatus and Limax maximus slugs, sGC may modulate the electrical oscillation of interneurons in the central olfactory pathway (57, 58) .
ARCHITECTURE OF SOLUBLE GUANYLATE CYCLASE
The rat sGC α1 and β1 subunits are 690 and 619 amino acids in length, respectively. These proteins are part of a large family of sGC subunits that are conserved in eukaryotes. Generally, there is the highest sequence variability at the N terminus of α-subunits and the greatest sequence identity at the C terminus of both the α-and β-proteins. Each sGC subunit consists of four distinct domains. The β1 subunit contains a N-terminal heme-binding domain, a Per/Arnt/Sim (PAS) domain, a coiled-coil domain, and a C-terminal catalytic domain (Figure 2 ) (reviewed in Reference 59).
Heme-Nitric Oxide and Oxygen Binding Domain
Experiments with sGC truncations and sitedirected mutants were necessary to localize the minimal heme-binding domain of sGC. These experiments involved the systematic mutation of conserved histidines (60) , expression of various truncations in E. coli (29) , and deletion of the β1 N terminus (61) . Taken together, these studies showed that the β1 N terminus constituted the heme-binding domain and suggested that histidine 105 (rat) was the proximal heme ligand. The sGC heme-binding domain has been localized to residues 1 to ∼194 on the β1 subunit (28) . Like the full-length sGC, the isolated heme domain binds NO and CO, but not O 2 . The N terminus of the α1 subunit has homology to the β1 N terminus and was shown to have affinity for heme despite lacking the proximal histidine ligand (30) . The sGC N terminus is part of a conserved family of proteins found in both prokaryotes and eukaryotes (62) . This family of proteins has been termed heme-nitric oxide binding (62) , sensor of nitric oxide (63) , and heme-nitric oxide and oxygen binding (H-NOX) (64) . H-NOX is the most used abbreviation and will be used throughout this review. To date, all of the characterized H-NOX proteins bind heme as well as the gaseous heme ligands NO and CO (reviewed in Reference 65) . Some H-NOX proteins, including β1 and β2, discriminate against O 2 binding, whereas others form a stable complex with O 2 . In eukaryotes, H-NOX proteins have only been found with the known sGC domain architecture. In bacteria, H-NOX domains can be found as proteins of ∼200 amino acids in length with a single predicted function or as a domain within a larger protein on the basis of sequence analysis programs. Additionally, the genes that encode these H-NOX proteins in bacteria are in proximity to genes that encode putative histidine kinases and diguanylate cyclases, or in some cases, a gene encodes the H-NOX as a domain within a larger protein, often fused to a methyl-accepting chemotaxis domain. It is likely that these proteins have an evolutionarily conserved function and serve as gas sensors in prokaryotes and eukaryotes.
Per/Arnt/Sim and Coiled-Coil Domains
The central region of sGC contains two domains of unresolved function. The domain closer to the N terminus is predicted to adopt a PAS-like fold. Typically, PAS domains mediate protein-protein interactions and have often been found to bind heme, a flavin, or a nucleotide (66) . The other domain, a coiled-coil domain, appears to be unique to sGC and shares no significant homology with any other protein in the National Center for Biotechnology Information protein database (http://www.ncbi. nlm.nih.gov/protein). The coiled-coil domain of the rat β1 subunit (residues 348-409) was isolated as a tetramer and structurally elucidated with X-ray crystallography (31) . This structural study, in addition to experiments involving site-directed mutagenesis of residues on the α1 subunit (67), a bimolecular fluorescence complementation assay in cells (68) , and structural analysis of homologs of the sGC PAS domain (69) , suggests that the central regions of both sGC subunits are important for the formation of a functional heterodimer.
Catalytic Domain
The C-terminal regions of the α1 and β1 proteins are highly homologous to the particulate guanylate cyclase and adenylate cyclase catalytic domains. In the 1990s, structural insights on the sGC catalytic domains came from homology models on the basis of crystal structures of the adenylate cyclase catalytic domains (70, 71) . These models identified key catalytic residues, including two conserved aspartate residues on the α1 subunit (D485 and D529, rat numbering), which are predicted to bind two Mg 2+ ions (72) . These residues are critical to catalysis as the associated metals likely activate both the nucleotide 3 -hydroxyl and the α-phosphate for the reaction, as well as stabilize the charge on the β-and γ-phosphates on both the substrate and product. Additionally, β1 N548 is proposed to orient the ribose ring for the reaction. Residues thought to be responsible for base recognition include E473 and C541 on the β1 subunit. Other residues on both α1 (R573) and β1 (R552) are thought to interact with the nucleotide triphosphate (72) . With the identification of these critical residues, predictions can be made about guanylate cyclase activity using sequence analysis. This type of analysis would correctly predict that the β2 isoform could function as a homodimer but that β1, α1, and α2 need a partner to be active.
The catalytic domains have now been localized to the C-terminal 467-690 and 414-619 residues of the α1 and β1 subunits, respectively (32) . These catalytic domains must form a heterodimer for cGMP to be synthesized, and in the full-length protein, the catalytic efficiency of the protein is dependent on the heme ligation state of the β1 H-NOX domain. sGC is highly selective for GTP as a substrate, but the protein can also cyclize 2 -d-GTP, GTP-γ-S, guanosine 5 -[β,γ-imido]-triphosphate (GMP-PNP), ITP, UTP, and ATP (73) (74) (75) . The isolated α1 cat β1 cat heterodimer is also selective for GTP but can synthesize cAMP from ATP (76) . Interestingly, the activity of α1 cat β1 cat is inhibited by the presence of the H-NOX domain [β1 or β1(1-385)] (32). 1, 2 This shows that these domains interact in trans and suggests that the NO mechanism of activation involves the relief of an inhibitory interaction between the H-NOX domain and the catalytic domains. In support of this sGC homologs: proteins with high sequence homology to mammalian sGCs Atypical sGCs: distinct subset of sGCs with reduced sensitivity to NO proposal, a fluorescence (or Förster) resonance energy transfer-based study showed that the N terminus of both the α1 and α2 subunits interact with the C terminus of the β1 subunit (77) . In addition to the heterodimeric rat sGC catalytic domains, the catalytic domain from the Chlamydomonas reinhardtii sGC (CYG12) has been biochemically characterized (78) . This protein, as well as Synechocystis PCC6803 Cya2, a particulate guanylate cyclase (79) , is discussed in more detail below.
SOLUBLE GUANYLATE CYCLASE HOMOLOGS
After the initial identification in mammals, it was not until the emergence of genome sequencing that the prevalence of sGC and sGC homologs in other organisms was fully realized. Full-length guanylate cyclases with domain architecture similar to the α1 and β1 subunits were found in several eukaryotic organisms. In prokaryotes, sGC-like H-NOX domains were found as stand-alone proteins or fused to other functional domains (62) . In some genomes, an sGC-like PAS domain was also identified. To date, the genes for sGC-like PAS domains are always found near genes that encode sGC-like H-NOX domains (62) .
Eukaryotic Atypical Soluble Guanylate Cyclases
As mentioned above, an increasing number of eukaryotic organisms are known to contain predicted sGCs. Some sGCs are very similar to the well-characterized rat α1 and β1 subunits, whereas others vary significantly. Collectively, these cyclases have been termed atypical sGCs (80) , owing to their distinct activation and dimerization properties. Some atypical sGCs exhibit a very surprising property-the ability to respond to O 2 .
The D. melanogaster genome contains five genes that code for sGCs. Two of these genes code for subunits with high homology to the α1 and β1 proteins and have been shown to form a highly NO-sensitive heterodimeric sGC (Gycα-99B and Gycβ-100B). The other three genes code for subunits with greater homology to the β2 protein (Gyc-88E, Gyc-89Da, and Gyc-89Db) (81) . Like β2, Gyc-88E can function as a homodimer, whereas Gyc-89Da and Gyc-89Db are only active as heterodimers (81) . Experiments with cells overexpressing Gyc-88E, Gyc-89Da, and Gyc-89Db indicate that cGMP synthesis in these cyclases is activated in the absence of O 2 (80) , and work with purified protein confirms that the Gyc-88E homodimer forms a stable complex with O 2 (82) . As expected, Gyc-88E also binds NO and CO, but there are data that support the role of these proteins in mediating behavioral responses in hyperoxic environments in D. melanogaster (83) . Interestingly, Gyc-88E is inhibited two-to threefold by the binding of NO, CO, and O 2 , a property that is quite distinct from the ligand-induced activation of the sGC α1β1 heterodimer.
On the basis of sequence analysis, atypical sGCs exist in several organisms, including Caenorhabditis elegans (GCY-31-GCY-37); however, worms do not contain a predicted NOS or NO-sensitive sGC. Seven β-like guanylate cyclases are contained within the C. elegans genome, and it is likely that each gene has an important functional role. GCY-35 is involved in social feeding (84) , and both GCY-35 and GCY-36 promote aggregation and bordering behaviors (85) . Significantly, these cGMPdependent behavioral responses are mediated by O 2 , which suggests the proteins function as O 2 sensors in vivo (84, 86) . In support of this proposal, the GCY-35 H-NOX domain was isolated and shown to bind O 2 (84) . Analysis of gcy-31 and gcy-33 mutants also implicates these genes in O 2 -dependent behavioral responses in C. elegans, and the proteins encoded by these genes (GCY-31 and GCY-33) likely function in distinct sensory neurons (BAG versus URX) when compared to GCY-35 and GCY-36 (87) .
Thus, a distinct class of cyclases exist, which bind O 2 and are inhibited by ligand binding, but there is currently no means to predict if a cyclase is activated or inhibited by gaseous ligand binding on the basis of sequence analysis. However, residues that contribute to gaseous ligand selectivity have been identified, as described below.
Prokaryotic Heme-Nitric Oxide and Oxygen Binding Proteins
Several species of bacteria are known to contain H-NOX proteins, and this number continues to increase as more genomes are sequenced. Interestingly, all of the isolated H-NOX domains from facultative aerobes have ligand-binding properties like sGC, namely they do not bind O 2 . In facultative aerobes, the bacterial members of the H-NOX family encode a single domain as a predicted stand-alone protein, and genes that encode either putative histidine kinases or diguanylate cyclases are found in the same predicted operon, suggesting that the domain has a role in two-component signaling in bacteria. In support of this hypothesis, an H-NOX domain and a predicted histidine kinase from Shewanella oneidensis were isolated and found to interact in vitro. Additionally, the functional interaction between the H-NOX and kinase was mediated by NO (88) . Vibrio fischeri also contains an H-NOX protein, termed H-NOX Vf , which is proposed to regulate a putative histidine kinase. In V. fischeri, H-NOX Vf was shown to regulate genes involved in iron uptake, and these same genes are modulated by the presence of NO (89) , suggesting that H-NOX Vf mediates gene expression by sensing NO. V. fischeri colonizes the light-emitting organ of the Hawaiian bobtail squid, Euprymna scolopes, and it is likely that this mutualistic host-microbe symbiosis is mediated by a NO/H-NOX Vf interaction. Some bacteria, like Rhodobacter sphaeroides and Nostoc punctiforme, also encode a predicted PAS-like domain upstream of the H-NOX gene (62) . The functional significance of this PAS domain to bacterial signaling is unknown, but it has been proposed to mediate protein dimerization (69) .
In obligate anaerobes, such as Thermonanaerobacter tengcongensis, the N-terminal H-NOX domain is fused to a C-terminal methyl-accepting chemotaxis protein, suggesting a role in a chemotactic/signaling function. This H-NOX domain was found to form a
NITRIC OXIDE SIGNALING IN BACTERIA
A currently expanding topic within biological studies on NO involves the role of the diatomic gas in bacterial signaling. NOS-like proteins have been identified in several prokaryotic organisms, including Bacillus anthracis, Bacillus subtilis, Sorangium cellulosum, and Streptomyces turgidiscabies. Additionally, a wide range of bacteria also have nitrite reductases, which generate NO as part of denitrifying, assimilatory, and dissimilatory pathways. This endogenously produced NO is known to regulate several transcription factors via S-nitrosation. There are also two potential classes of prokaryotic heme-based NO sensors: globin-like proteins and H-NOX proteins. Microbial globin-like proteins bind O 2 , NO, and CO, and are thought to be involved in the nitrosative stress response. Some H-NOX proteins bind O 2 , in addition to CO and NO, whereas others exclude O 2 binding. The genes that code for these H-NOX proteins are found in the same operons as predicted histidine kinases or diguanylate cyclases. In vitro studies have shown that the H-NOX protein and histidine kinase from S. oneidensis interact in a NO-dependent manner, but the physiological significance of this interaction is unknown. However, NO is known to be important for the symbiosis between the bobtail squid and V. fischeri, where the H-NOX from V. fischeri regulates colonization of the bacteria within the symbiotic host squid by a mechanism that is dependent on NO. Further experiments in different microbial systems will likely uncover additional NO-dependent signaling processes in bacteria.
very stable heme-O 2 complex (K d = 90 nM) (90), a molecular distinction from the H-NOX domains from aerobic bacteria. The isolation and characterization of the T. tengcongensis H-NOX domain have significantly influenced current understanding of sGC because it was the first H-NOX domain to be structurally determined, and, moreover, it was crystallized bound to the diatomic ligand O 2 (63, 64) .
Thus far, these proteins have been used as tools for probing sGC structure and regulation, but functional studies in microbial systems (see the sidebar titled Nitric Oxide Signaling in Bacteria) will be particularly interesting as the variable ligand-binding properties of these H-NOXs may have consequences for their ability to respond to different gases, i.e., some proteins may sense O 2 in addition to NO or CO.
H-NOX domain PAS domain
Catalytic domain CC domain 
STRUCTURAL INSIGHTS FROM STUDIES ON SOLUBLE GUANYLATE CYCLASE AND ITS HOMOLOGS
An increasing number of sGC homologs have been isolated and characterized. Significantly, some of these homologs have been amenable to crystallography, thus providing a foundation for structural proposals on the β1 H-NOX, PAS, and catalytic domains. The first crystal structure of an sGC-like domain was that of the O 2 -binding H-NOX domain (residues 1-188) from T. tengcongensis (Figure 3) (63, 64) . This protein crystallized in two different six-coordinate heme states, with O 2 bound to the reduced heme iron and in the oxidized heme state. These reports identified several amino acids with critical structural roles that are highly conserved within the H-NOX family. Among the highly conserved amino acids was the T. tengcongensis H-NOX heme-coordinating histidine (H102) and three residues that stabilize heme binding (Figure 4) . Specifically, arginine (R135) is critical to the coordination of the heme propionate groups and forms a hydrogen bond with both carboxyl groups, and tyrosine (Y135) and serine (S133) coordinate to one of the heme carboxyl groups. Together, these residues form a YxSxR motif that is strictly conserved in H-NOX proteins. The proximal histidine, arginine, and tyrosine had been previously identified as critical residues for heme binding in the sGC β1 subunit on the basis of mutagenesis studies (91, 92) , and the role of these residues became clear when the T. tengcongensis H-NOX structure was solved.
Another striking characteristic of the T. tengcongensis H-NOX structure is a highly nonplanar heme conformation; it contains one of the most highly distorted hemes reported in the Protein Data Bank. Interestingly, different molecules of the O 2 -bound H-NOX structure exhibit varying degrees of deformation, suggesting that the heme can exist in a range of conformations. This proposal is supported by the observation that the crystal structure of the H-NOX protein from Nostoc sp. contains a moderately distorted heme (93) . This heme distortion is not an artifact of crystallization as it is also observed in solution on the basis of an NMR study of the S. oneidensis H-NOX (94) and resonance Raman experiments with T. tengcongensis H-NOX (95) and α1β1 sGC (96) (97) (98) . In fact, the dynamic range of heme conformations can be accessed in solution by site-directed mutagenesis (95) or, in the case of sGC, by addition of the allosteric activators YC-1 or BAY 41-2272 (96-98) . Specifically, the α1β1 sGC heme becomes more planar upon activator binding; however, it is unclear if this is a cause or consequence of enzyme activation. Thus, although the functional importance of heme distortion in sGC activation remains unknown, there is a potential to utilize changes in distortion in biological responses.
Among the residues thought to be critical to maintaining the nonplanar heme conformation are I5, D45, R135 (in the YxSxR motif ), L144, and P115, all of which are highly conserved in H-NOX proteins (64). In T. tengcongensis H-NOX, mutation of proline 115 to alanine leads to relaxation of the distorted heme (95, 99) . This heme relaxation was not observed after mutation of proline 118 to alanine (P115 in T. tengcongensis H-NOX) in α1β1 sGC (96); however, it is not surprising that additional residues or domain interactions are important for maintaining the heme conformation in the mammalian protein.
The crystal structure of the non-O 2 -binding H-NOX from Nostoc sp. has been solved in the five-coordinate unligated state and as the six-coordinate NO-and CO-heme complexes (93 S. oneidensis H-NOX, mutation of this residue to glycine leads to the isolation of apoprotein. Similar to previous reports with other heme proteins (92, 102) , heme binding in S. oneidensis H-NOX H103G can be rescued by imidazole. H103 is in α-helix F, and in the heme-binding rescued mutant, this helix is free to adopt a position like that in a five-coordinate NO complex. The S. oneidensis H103G H-NOX structure, along with the structure of the weakly active wild-type Fe II -CO S. oneidensis H-NOX, was solved by NMR. The solution structures of both of these proteins indicate that major changes in heme planarity and H-NOX conformation occur upon cleavage of the proximal histidine heme ligand.
Major structural changes are also observed between the unbound and BAY 58-2667-bound Nostoc sp. H-NOX structures (101) . BAY 58-2667 is a NO-and heme-independent sGC activator (103) and is a candidate to treat decompensated heart failure. The crystal structure shows that BAY 58-2667 is able to displace the heme and occupy the heme-binding site, thereby leading to a shift in the α-helix F that contains the proximal histidine residue. Additional experiments mutating residues around the proximal histidine on α-helix F suggest that D102 could play a critical role in enzyme activation (104) . In addition to providing a structural basis for proposals on sGC activation, these H-NOX structures enabled the development of homology models of the heme-binding domains of both NO-sensitive and atypical cyclases (28, 63, 105, 106) , as well as density functional theory analysis and computer simulations to address questions concerning structural dynamics (107, 108) .
The crystal structure of a domain from the N. punctiforme signal transduction histidine kinase has also been determined (Figure 3) . This domain has high sequence identity (35%-38%) to the sGC PAS domain, and the crystal structure showed that the domain dimerized and adopted a PAS fold (69) . There is no structure of a eukaryotic sGC PAS domain, but the crystal structure of the coiled-coil domain of the β1 subunit has been solved (Figure 3 
) (31).
This structure indicates that the coiled-coil domain forms a tetramer composed of a dimer of dimers. In addition to identifying potential residues involved in mediating dimerization, the authors propose that interhelix salt-bridge formation selects for heterodimerization versus homodimerization in sGCs on the basis of their structure (31) .
The catalytic domains of two different functional guanylate cyclases (78, 79) , and the inactive human β1β1 catalytic domains [Protein Data Bank (pdb) code 2WZ1], have been structurally elucidated (Figure 3) . The functional cyclase domains include a soluble homodimeric guanylate cyclase from the eukaryotic algae C. reinhardtii (78) and a particulate homodimeric guanylate cyclase from the unicellular cyanobacterium Synechocystis PCC6803 Cya2 (79) . Both proteins cyclize GTP and likely contain two catalytic sites per dimer. On the basis of kinetic analysis of cGMP synthesis, the eukaryotic algae catalytic domains exhibit positive cooperativity with a Hill coefficient of 1.5. This is similar to the cooperativity observed in particulate guanylate cyclases and may be a common feature of homodimeric sGCs (78) . The α1β1 heterodimer contains one active site and a proposed pseudosymmetric site. This proposed pseudosymmetric site is thought to constitute an allosteric nucleotide-binding site that communicates with the catalytic nucleotide-binding site. On the basis of the algae sGC structure, this communication may involve residues contained on the β2-β3 loop of each catalytic domain monomer. Specifically, the interaction of D527 or E523 (C. reinhardtii sGC numbering) with a nucleotide in one active site could alter the loop conformation and thus lead to a conformational change in the other nucleotide-binding site (78) .
Unfortunately, both structures are in an inactive state, but they confirm the guanylate cyclase residues critical to metal binding and nucleotide recognition that were predicted from the adenylate cyclase crystal structures. Together, the reports of the C. reinhardtii sGC and Cya2 catalytic domains provided the first structures of a guanylate cyclase, and the structures show that there is high homology between guanylate cyclase and adenylate cyclase domains; however, the elucidation of a mammalian heterodimeric structure remains an important task for understanding sGC regulation. Details about how movement in the β1 H-NOX domain affects the catalytic domain, and the role of the PAS and coiled-coil domain in relaying a signal from the H-NOX domain, may remain open questions until the full-length sGC structure is elucidated.
LIGAND SELECTIVITY
The α1β1 heme environment is unique when compared to the globins because the cofactor efficiently binds NO while having no affinity for O 2 . Additionally, the α1β1 heterodimer exhibits an extremely slow rate of oxidation and has among the highest midpoint potential reported for a high-spin heme protein (+187 mV versus +58 mV for myoglobin) (109) . This ability of mammalian sGC to select against O 2 binding is important for it to function as a NO sensor, as O 2 is present at much higher levels than NO in vivo, and Fe II -O 2 proteins react rapidly with NO. Hemoproteins in the Fe III oxidation state also form weak NO complexes and could inadvertently serve as a sink for NO. Since the discovery of sGC, several potential mechanisms of ligand discrimination against O 2 have been proposed, including a weak FeHis bond strength, a negatively charged distal pocket, and a sterically constrained distal pocket (109) (110) (111) . One proposal on the mechanism by which α1β1 excludes O 2 is based on analysis of the T. tengcongensis H-NOX crystal structure (63, 64) . T. tengcongensis H-NOX stabilizes O 2 binding with a hydrogen-bonding network involving a tyrosine (Y140), a tryptophan (W9), and an asparagine (N74) (Figure 4) . These residues appear to be absent in the β1 H-NOX protein and other O 2 -excluding H-NOXs on the basis of primary sequence alignments and homology modeling. Conversely, several atypical sGCs, including the known O 2 -binding cyclase Gyc-88E, encode a tyrosine that aligns with T. tengcongensis H-NOX Y140. Therefore, the absence of a hydrogen bond donor in the α1β1 distal heme pocket, and the subsequent increase in the O 2 off rate, likely contributes to the protein's inability to form a stable Fe II -O 2 complex (64, 90). Molecular dynamics simulations of O 2 -binding and non-O 2 -binding H-NOX proteins suggest that they have varying tunnel systems, which may also contribute to their different ligand-binding properties (112) , and site-directed mutagenesis within the proposed tunnel indicates that it is important for diffusion of gaseous ligands (113) .
Several biochemical studies aimed at probing ligand selectivity in sGC have been reported. The distal-pocket tyrosine in the O 2 -binding T. tengcongensis H-NOX was mutated to leucine (Y140L), and this mutation significantly reduced O 2 affinity. Additionally, the introduction of a distal-pocket tyrosine in a non-O 2 -binding H-NOX from Legionella pneumophilia (L2 H-NOX) enabled the protein to bind O 2 (90) . Mutagenesis studies introducing a tyrosine into the distal pocket of the β1 H-NOX-PAS domain β1(1-385) also produced a protein that was capable of binding O 2 (90) , but the same mutation in full-length sGC did not facilitate O 2 binding (106, 114) . However, the introduction of a tyrosine and glutamine into the β1 heme pocket (I145Y/I149Q) resulted in a full-length α1β1 protein with altered reactivity to O 2 (105) . A homology model of the O 2 -binding guanylate cyclase Gyc-88E places these amino acids within the predicted distal heme pocket. Thus, some O 2 -binding guanylate cyclases may utilize a Tyr/Gln hydrogen-bonding network, similar to several truncated globins (115) (116) (117) (118) , to stabilize ligand binding. The marked variability in O 2 reactivity between fulllength sGC and heme-binding truncations of the β1 protein highlights the potential for other sGC domains to influence ligand selectivity. Thus, despite significant progress in our understanding of ligand discrimination in sGC, including the identification of residues critical for stabilizing O 2 binding in sGC homologs, there remain some unknown variables that may contribute to the ligand specificity of these heme proteins.
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REGULATION OF SOLUBLE GUANYLATE CYCLASE BY NITRIC OXIDE
Physiological responses to NO, such as smooth muscle relaxation, are rapidly induced by low levels of the diatomic gas. In cells, cGMP levels rise within milliseconds after exposure to nanomolar concentrations of NO, and this fast response occurs because sGC efficiently binds to and is activated by NO. When NO dissociates from the protein, the amount of cGMP decreases to a basal level. Thus, both the rise and fall of cGMP levels must be tightly regulated for proper function of cGMPdependent processes. Upon repeated exposure to NO or NO-donors, like GTN, maximal sGC activation decreases, and this process is called sGC desensitization. sGC activation, deactivation, and desensitization have been extensively studied in vivo and in vitro. A major challenge with understanding these processes occurs when reconciling discrepancies in results obtained with purified protein versus sGC examined in the cellular milieu.
Activation and Nitric Oxide Association
As mentioned above, the activation of sGC in vitro and in vivo is rapid (occurs in milliseconds). Using a NO donor or NO gas, the apparent 50% effective concentration for NO acting on purified sGC is between 80 and 250 nM (119, 120) . A similar potency of NO has been measured in rat cerebellar cells (apparent 50% effective concentration ∼45 nM) (121) . On the basis of studies with purified protein, it is known that NO binds to the heme of sGC at a diffusion-controlled rate to form an initial six-coordinate complex, which rapidly converts to a five-coordinate ferrous nitrosyl (Fe II -NO) complex (120) . The six-coordinate Fe II -NO complex is not stable and has only been observed with time-resolved spectroscopic methods (120, 122, 123) . The presence of Mg 2+ GTP or Mg 2+ /cGMP/pyrophosphate (PP i ) accelerates the formation of the five-coordinate sGC-NO complex, and this effect is blocked by the addition of ATP (122, 123) .
Breakage of the Fe-His bond is thought to be a critical step in the activation of sGC by NO; however, recent data have shown that NO coordination to the heme is not sufficient for full activation ex vivo (122, 123) . A low-activity Fe II -NO complex can be formed in the presence of stoichiometric amounts of NO, whereas a high-activity Fe II -NO complex is formed in the presence of excess NO. These two fivecoordinate Fe II -NO species are indistinguishable by electronic absorption spectroscopy, but they exhibit distinct signals by electron paramagnetic spectroscopy (124) . Preincubation of sGC with substrate Mg 2+ GTP or the reaction products Mg 2+ /cGMP/PP i produces a highactivity Fe II -NO species in the presence of stoichiometric amounts of NO (123) . ATP can compete with the GTP effect, and in the presence of ATP and GTP, a low-activity Fe II -NO species is formed (122) . This clear difference in sGC activity indicates that preincubation of the enzyme with the small molecules leads to a conformational change such that sGC is highly activated by low levels of NO. It was also found that the small-molecule YC-1 can activate the low-activity Fe II -NO complex to the high-activity state (122, 125) . Thus, both YC-1 and excess NO activate the low-activity five-coordinate Fe II -NO complex that is formed in the absence of substrate or reaction products.
Two mechanisms have been proposed to account for the varying activity of the sGC Fe II -NO complex observed ex vivo. One proposal is that excess NO activates the Fe II -NO complex by binding to nonheme sites on the protein (122) . If NO binds to a nonheme site, it is likely that cysteines would comprise this binding site as experiments with the thiol reactive reagent methyl methanethiosulfonate suggest that reduced cysteines are necessary for the mechanism of NO activation (125) . The second proposal regarding sGC activation involves excess NO binding to the heme to form a transient dinitrosyl complex, which then converts Model of nitric oxide (NO) dissociation and deactivation of NO-stimulated soluble guanylate cyclase (sGC) in vitro. The sGC-NO complex consists of two different five-coordinate species that slowly interconvert. NO dissociation from the sGC heme is slow, whereas NO deactivation is rapid on the basis of in vitro measurements, including spectroscopic methods (Abs max indicated in nanometers) and cyclic GMP analysis. The presence of allosteric modulators (GTP, ATP, YC-1, or BAY 41-2272) influences the deactivation and NO dissociation rates differently. Taken together, these results indicate that the deactivated sGC species is distinct from the unligated sGC species (431 nm) produced from NO dissociation from the heme and suggests that two molecules of NO are able to bind to sGC.
to a five-coordinate complex with NO bound in the proximal heme pocket (123) . Such proximal heme pocket NO binding has been observed with other histidine-ligated heme proteins including cytochrome c (126) . The importance of the two different sGC-NO states in vivo remains unclear. One report examining sGC activity in endothelial cells proposed that enzyme activation by excess NO is important for the physiological activation of sGC (125) , whereas another report examining sGC activation in rat platelets and cerebellar cells proposed that the observed activation kinetics were consistent with a single NObinding event (127) . Thus, further experiments are necessary to resolve the mechanism of sGC activation in vivo.
Deactivation and Nitric Oxide Dissociation
Deactivation of the sGC Fe II -NO complex has been extensively studied to understand the lifetime of the NO signal in vivo. This process was originally thought to correlate directly with NO dissociation from the sGC heme; however, as mentioned above, a NO-bound protein that is partially activated has been characterized. This indicates that sGC deactivation and NO dissociation from the heme cofactor are not explicitly linked, and thus, deactivation and heme-NO dissociation measurements cannot be used interchangeably (Figure 5) .
NO-induced relaxation of smooth muscle cells dissipates within seconds upon removal of free NO due to the deactivation of sGC (128) . sGC deactivation, the rate of decline in cGMP synthesis after an activator is removed, has been determined in various cells and with purified protein. In cells, sGC deactivation is rapid (t 1/2 < 5 s at 37
• C) in the presence of an NO trap (oxyhemoglobin) to limit NO rebinding (121, 129) . Activity assays with the cytosol of retina homogenate indicate that the sGC-NO deactivation rate is not influenced by the presence www.annualreviews.org • Structure and Regulation of SGCS-nitrosation: posttranslational modification involving the oxidative addition of NO to a thiol of Mg 2+ GTP and is only slightly increased by the presence of reducing agents, such as glutathione and dithiothreitol (129) . In agreement with cellular data, the deactivation rate of purified protein is also rapid (t 1/2 ∼ 4 s at 37
• C) (130) . This deactivation rate is unaffected by the presence of a GTP analog and/or ATP (122) , but the rate is significantly decreased (140-fold) by the presence of the allosteric activator YC-1 (t 1/2 > 10 min at 37
• C) (130) . The rate of NO dissociation from the sGC heme must be spectroscopically determined, and as a consequence, this rate has only been measured in vitro. Early reports found that the sGC heme-NO complex is very stable (t 1/2 ∼ 87 min at 37
• C) in the absence of NO traps or allosteric effectors (23, 131) . Unlike most heme proteins, which rapidly oxidize in the presence of O 2 and NO, a reduced Fe II protein is formed when NO dissociates from the sGC heme. Using a trap to scavenge NO, like CO/dithionite or oxymyoglobin, the dissociation rate can be determined without interference from NO rebinding. Reductants like dithiothreitol or glutathione react with NO and can also be used to prevent rebinding (23) . With these NO trapping methods, it was determined that the NO dissociation rate is relatively slow (t 1/2 = 3-8 min at 37
• C) (23, 27, 131) compared to previously determined deactivation rates but increases (∼50-fold) in the presence of Mg 2+ GTP (131) . However, if Mg 2+ GTP is added to sGC after the NO complex is formed, it has no effect on the dissociation rate (23, 123, 131) , indicating that the allosteric affect of GTP is dependent on substrate binding in the absence of NO. In contrast to the previously discussed deactivation results, the GTP effect on the dissociation rate is inhibited by the presence of ATP (122) . Therefore, in the presence of both GTP and ATP, sGC exhibits a slow NO dissociation rate but rapid deactivation. In the presence of YC-1, the NO dissociation rate increases (27) , whereas the deactivation rate decreases (130) . A model summarizing deactivation of sGC and NO dissociation is shown in Figure 5 .
Desensitization
The sGC response to GTN or NO decreases upon repeated exposure to the activators. This desensitization is rapid, such that a single pretreatment of cells with GTN or NO can significantly reduce cGMP stimulation upon the second exposure (132, 133) . Purified protein in the absence of reducing agents also exhibits a decrease in NO-stimulated activity after pretreatment with NO. This desensitization has implications for therapies used in the treatment of heart disease as this loss of responsiveness, or tolerance, is also observed when organic nitrates are administered to patients with angina pectoris (134) . As a consequence, these drugs cannot be used repeatedly. Over the past 30 years, several proposals have been advanced to explain the phenomenon of tolerance, including increased PDE activity (135) , inhibition of mitochondrial aldehyde dehydrogenase (136) , and most recently S-nitrosation (137, 138) . There is currently significant evidence in support of the proposal that nitrosation, the oxidative addition of NO to a thiol, contributes to sGC desensitization.
It has long been known that thiol oxidation inhibits sGC activity. Cysteines can oxidize sequentially to form a sulfenic acid, sulfinic acid, sulfonic acid, or a disulfide bond in the presence of O 2 , or form a nitrosothiol in the presence of NO and O 2 . In the 1980s, the formation of sGC-cysteine mixed disulfides was shown to reversibly inhibit cGMP production (139) . More recently, the induction of reactive O 2 species in vascular smooth muscle cells was found to inhibit cGMP synthesis and lead to the oxidative modification of sGC cysteines (140) . Additionally, the thiol modifying reagent methyl methanethiosulfonate was shown to inhibit sGC activity in vitro and in primary endothelial cells. In vitro sGC inhibition by methyl methanethiosulfonate is reversible, and the molecule was shown to modify several cysteines on both the α1 and β1 subunits (125) . The NO-dependent oxidation of cysteines on sGC has also been reported. sGC is S-nitrosated in the presence of low levels Nitrate tolerance: loss of sensitivity to nitrates of NO, and this modification has been linked to a reduction in NO-stimulated activity (137) . In addition, GTN has been shown to induce sGC S-nitrosation and desensitization in a concentration-dependent manner (138) . Cysteines on both the α1 (C243) and β1 (C122) subunits have been identified as targets of this oxidative modification.
It has become clear that sGC requires free thiols for proper function. Without a crystal structure, it is difficult to address why these cysteines are necessary for NO-induced sGC activation. Perhaps free thiols are important to the structural integrity of the protein, involved in a conformational change to the activated enzyme state, and/or directly involved in the NO mechanism of activation. If sGC S-nitrosation is the primary molecular mechanism of nitrate tolerance, then molecules developed to protect these thiols from oxidation could be useful for the treatment of diseases related to sGC dysfunction. Furthermore, the apo-and heme-oxidized sGC states have been proposed to be physiologically relevant sGC species in diseased tissue.
MODULATORS OF SOLUBLE GUANYLATE CYCLASE ACTIVITY Soluble Guanylate Cyclase Activators
sGC is a therapeutic target in the treatment of heart disease. Organic nitrites and organic nitrates (like GTN) are perhaps the earliest agents used to target the NO/cGMP-signaling pathway and have been in clinical use for over 100 years. The first description of GTN as a therapeutic agent for the treatment of angina pectoris appeared in 1879, and it remains the drug of choice to treat the disease. Despite decades of clinical use, the precise mechanism of action of GTN is unknown; however, it is generally considered a nitrovasodilator or a NO-donor. This NO release may occur by spontaneous decomposition or bioconversion to result in NO-dependent sGC activation.
In addition to NO, other known heme ligands, including CO, nitrosoalkanes, and alkyl isocyanides, can bind to the sGC heme but can only weakly activate the protein (17, 141, 142) . The binding of these compounds leads to the formation of a six-coordinate complex and to a two-to fourfold increase in the rate of cGMP production, significantly lower than the 100-to 400-fold increase in cGMP synthesis observed with NO. Other compounds that have been reported to activate sGC by targeting the hemebinding pocket include protoporphyrin IX (15) and Co 2+ protoporphyrin IX (143) . It has become clear that small molecules can modulate the activity of sGC and that new therapeutics might be developed for the treatment of various diseases. This prompted a search for novel sGC activators, and several compounds were screened for the ability to increase cGMP levels in cell lysates. Such a screen led to the identification of YC-1, a benzylindazole derivative that activates sGC without coordinating to the heme (144) . YC-1 only activates the Fe II -unligated sGC state two-to fourfold but significantly increases sGC activity when a ligand is bound at the Fe II heme (141, 142, 145, 146) . This synergistic activation leads to an Fe II -CO complex that is activated 100-to 400-fold and an Fe II -NO complex that is activated 200-to 800-fold. The molecular mechanism of YC-1 activation is unknown. Experiments with equilibrium dialysis suggest that sGC binds one equivalent of YC-1 per heterodimer (147) . This binding site may be contained within the N terminus of the α1 subunit (33, 148) or within the pseudosymmetric substrate site (149) (150) (151) . What is clear is that YC-1 binding to sGC induces a conformational change that elevates cGMP production. This highly active conformational state has been characterized by spectroscopic methods, including electronic absorption (152) , resonance Raman spectroscopy (147, 153) , and electron paramagnetic resonance spectroscopy (124, 147) . There are also clear kinetic effects of adding YC-1 to CO-or NO-bound sGC (27, 130, 154) .
The discovery of the novel sGC stimulator YC-1 led several groups to carry out structure activity relationships to improve both the solubility and efficacy of YC- (155, 156) , it is commonly accepted that the molecule activates sGC without coordinating to the heme. Collectively, these molecules constitute a novel class of sGC stimulators that require the presence of the heme moiety and have the ability to synergistically stimulate sGC with both NO and CO. These molecules were promising drug candidates but had unfavorable drug metabolism. Medicinal chemistry efforts to reduce the problems associated with these compounds led to the discovery of BAY 63-2521 (riociguat). This compound induces vasodilation by activating sGC and is currently in Phase III clinical trails (reviewed in Reference 157) .
There are also small-molecule activators that target heme-oxidized or -deficient sGC; therefore, they are classified as NO and heme independent. One of these is BAY 58-2667 (Cinaciguat) (158) . BAY 58-2667 is generally cited as an activator of both heme-deficient and heme-oxidized (Fe III ) sGC (158), but there is one report that proposes the molecule exclusively targets the heme-deficient sGC state (159) . BAY 58-2667 is proposed to activate sGC by binding within the heme pocket, thereby serving as a mimic of the heme-NO complex (91, 101) . In addition to activating the enzyme, BAY 58-2667 also stabilizes sGC and protects the protein from degradation (160) . In rats, BAY 58-2667 was shown to lower blood pressure (161) and protect against ischemic injury (162) , and the compound has been tested on patients with acute decompensated heart failure (163) (164) (165) .
Soluble Guanylate Cyclase Inhibitors
There has been significantly more work on identifying sGC activators, but compounds that inhibit sGC activity have also been reported. These compounds are not as selective as the identified activators and include general oxidants, molecules that target hemoproteins, and nucleotide cyclase inhibitors. Compounds proposed to target the sGC H-NOX domain include heme, hematin (15) , and 1H- [1, 2, 4] oxadiazolol [4,3-a] quinoxalin-1-one (ODQ) (166) . These compounds inhibit sGC by oxidation of the ferrous iron in the heme cofactor. Molecules such as hydrogen peroxide, superoxide, cystine, and Snitrosocysteine also reduce cGMP production by oxidizing critical residues on sGC (138) (139) (140) . Other known sGC inhibitors, such as LY83583 (167) and methylene blue (168) , inhibit the enzyme via generation of superoxide anion (169, 170) . Inhibition of sGC by these oxidants emphasizes the importance of the redox environment for proper protein function.
Substrate analogs that bind to the sGC catalytic domain inhibit guanylate cyclase activity. To date, several such analogs have been identified as sGC inhibitors, including, but not limited to, ITP, XTP, CTP, ATP, ADP, AMP, 2 -deoxyadenosine 5 -diphosphate (2 -dADP), GDP, guanosine-5 -[(α,β)-methylene]triphosphate (GMP-CPP), and N-methylanthraniloyl (MANT)-nucleotides (75, 151, 171, 172) . These compounds inhibit sGC by varying mechanisms depending on whether they target the pseudosymmetric site in addition to the substrate-binding site. For example, AMP-PNP is a competitive inhibitor (151) , while ATP is a mixed-type inhibitor and substrate (76) .
SUMMARY POINTS
1. Soluble guanylate cyclase (sGC) is the most thoroughly characterized receptor for the signaling molecule nitric oxide (NO). NO activation of sGC is essential to several physiological processes, and thus dysfunction in sGC is linked to several diseases. Compounds that modulate sGC are in clinical trails for the treatment of heart disease.
2. Each sGC subunit consists of an H-NOX, PAS, coiled-coil, and catalytic domain. Functional truncations of sGC include the isolated β1 H-NOX domain, the β1 coiled-coil domain, and the α1β1 catalytic domains.
3. Genome mining has revealed that several predicted proteins exist with high sequence homology to sGC, including prokaryotic H-NOXs and eukaryotic NO-sensitive and atypical sGCs.
4. The structure of full-length sGC is not yet determined, but studies on H-NOXs and sGC homologs have illuminated many important structural features of the enzyme. On the basis of these studies, sGC likely contains a hydrophobic heme-binding pocket, without a distal-pocket hydrogen bond donor, and heterodimerization is mediated by contacts on the PAS, coiled-coil, and catalytic domains.
5. α1β1 sGC does not form a stable complex with O 2 , but several sGC homologs bind O 2 .
Hydrogen bond donors in the heme-distal pocket are often found in the H-NOXs and atypical sGCs that bind O 2 . The presence or absence of amino acids capable of forming a hydrogen bond in the heme-distal pocket contributes to selectivity for gaseous ligands.
6. sGC regulation by NO and nucleotides in vitro is complex. Two molecules of NO can bind to the protein, and both GTP and ATP can influence NO binding, dissociation, and activation. In cells, it is likely that NO, GTP, and ATP modulate cGMP production, and both reduced cysteines and a reduced heme iron are important for this activity.
FUTURE ISSUES
Over the past few years, sGC has been implicated in an expanding number of physiological processes and diseases. Continued progress toward elucidating the mechanism of sGC activation is important in the development of therapeutics to treat disorders relating to the NO-signaling pathway. Despite significant advances in our understanding of NO as a signaling agent, many questions remain unanswered. In mammals, the sGC response to NO is complicated, and the precise events that lead to activation remain a topic of debate. Furthermore, sGC is regulated by allosteric interactions with ATP and GTP, and there are likely other important factors, including S-nitrosation and phosphorylation, that modulate sGC activity. Future experiments considering these factors will be necessary to determine the influence of each regulatory factor in the activation, deactivation, and desensitization of sGC. How do the α1 and β1 subunits interact when sGC is activated? What is the nature of the allosteric activator-binding site? What conformational changes occur when ligands bind to sGC? All of these questions may be addressed with the structural elucidation of the full-length heterodimeric protein. Additionally, structural analysis may provide insight into the molecular mechanisms that lead to sGC dysfunction.
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